Milestone Pharmaceuticals Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Milestone Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q2 2024.
Milestone Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$9.66M, a 41.2% increase year-over-year.
Milestone Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$49.3M, a 18.8% increase year-over-year.
Milestone Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$61.1M, a 2.44% decline from 2022.
Milestone Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$59.6M, a 38.5% decline from 2021.
Milestone Pharmaceuticals Inc. annual Operating Income (Loss) for 2021 was -$43.1M, a 15.1% increase from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	-$49.3M	-$9.66M	+$6.77M	+41.2%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	-$56.1M	-$10.5M	+$5.03M	+32.4%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-13
Q4 2023	-$61.1M	-$13.8M	-$41K	-0.3%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-21
Q3 2023	-$61.1M	-$15.4M	-$330K	-2.2%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-13
Q2 2023	-$60.7M	-$16.4M	+$370K	+2.2%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	-$61.1M	-$15.5M	-$1.46M	-10.4%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-13
Q4 2022	-$59.6M	-$13.8M	+$3.16M	+18.7%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-21
Q3 2022	-$62.8M	-$15M	-$757K	-5.3%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-13
Q2 2022	-$62M	-$16.8M	-$17.5M	-2460%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	-$44.5M	-$14M	-$1.45M	-11.5%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	-$43.1M	-$16.9M	-$8.16M	-93.1%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-29
Q3 2021	-$34.9M	-$14.3M	-$2.19M	-18.1%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-10
Q2 2021	-$32.7M	$712K	+$13.8M		Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-10
Q1 2021	-$46.5M	-$12.6M	+$4.16M	+24.8%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	-$50.7M	-$8.76M	+$10.1M	+53.6%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-24
Q3 2020	-$60.8M	-$12.1M	+$1.64M	+11.9%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-12
Q2 2020	-$62.5M	-$13.1M	+$1.23M	+8.57%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-11
Q1 2020	-$63.7M	-$16.8M	-$5.83M	-53.3%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-17
Q4 2019	-$57.9M	-$18.9M	-$8.79M	-86.9%	Oct 1, 2019	Dec 31, 2019	10-K	2021-03-29
Q3 2019	-$49.1M	-$13.7M	-$7.94M	-137%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-13
Q2 2019	-$41.2M	-$14.3M	-$10.7M	-290%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-12
Q1 2019	-$30.5M	-$10.9M	-$6.68M	-157%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-14
Q4 2018	-$23.8M	-$10.1M			Oct 1, 2018	Dec 31, 2018	10-K/A	2020-10-23
Q3 2018		-$5.79M			Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-13
Q2 2018		-$3.68M			Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-13
Q1 2018		-$4.26M			Jan 1, 2018	Mar 31, 2018	10-Q	2019-06-19

* An asterisk sign (*) next to the value indicates that the value is likely invalid.